ILMN - Illumina Inc Stock Price, Fair Value and News

120.45USD+3.15 (+2.69%)Market Closed

Market Summary

USD120.45+3.15

Market Closed

2.69%

ILMN Stock Price

View Fullscreen

ILMN RSI Chart

ILMN Valuation

Market Cap

19.2B

Price/Earnings (Trailing)

-14.87

Price/Sales (Trailing)

4.27

EV/EBITDA

-21.63

Price/Free Cashflow

52.43

ILMN Price/Sales (Trailing)

ILMN Profitability

Operating Margin

61.35%

EBT Margin

-25.54%

Return on Equity

-22.5%

Return on Assets

-12.85%

Free Cashflow Yield

1.91%

ILMN Fundamentals

ILMN Revenue

Revenue (TTM)

4.5B

Rev. Growth (Yr)

-1.01%

Rev. Growth (Qtr)

-4.1%

ILMN Earnings

Earnings (TTM)

-1.3B

Earnings Growth (Yr)

-4.3K%

Earnings Growth (Qtr)

28.41%

Breaking Down ILMN Revenue

Last 7 days

5.2%

Last 30 days

14.0%

Last 90 days

-1.5%

Trailing 12 Months

-36.5%

How does ILMN drawdown profile look like?

ILMN Financial Health

Current Ratio

1.75

ILMN Investor Care

Shares Dilution (1Y)

0.76%

Diluted EPS (TTM)

-8.15

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	4.5B	0	0	0
2023	4.4B	4.5B	4.5B	4.5B
2022	4.7B	4.7B	4.7B	4.6B
2021	3.5B	4.0B	4.3B	4.5B
2020	3.6B	3.4B	3.2B	3.2B
2019	3.4B	3.4B	3.5B	3.5B
2018	2.9B	3.1B	3.2B	3.3B
2017	2.4B	2.5B	2.6B	2.8B
2016	2.3B	2.3B	2.4B	2.4B
2015	2.0B	2.1B	2.1B	2.2B
2014	1.5B	1.6B	1.7B	1.9B
2013	1.2B	1.3B	1.3B	1.4B
2012	1.0B	1.0B	1.1B	1.1B
2011	993.1M	1.1B	1.1B	1.1B
2010	692.7M	743.1M	822.0M	902.7M
2009	0	604.3M	635.3M	666.3M
2008	0	0	0	573.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About Illumina Inc

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. Further, it provides whole-genome sequencing, genotyping, NIPT, and product support services; and Galleri, a multi-cancer early detection test. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Further, it markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

CEO	Mr. Charles E. Dadswell Esq.
WEBSITE	illumina.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	11500

Illumina Inc Frequently Asked Questions

What is the ticker symbol for Illumina Inc? What does ILMN stand for in stocks?

ILMN is the stock ticker symbol of Illumina Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Illumina Inc (ILMN)?

As of Fri Jul 26 2024, market cap of Illumina Inc is 19.19 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ILMN stock?

You can check ILMN's fair value in chart for subscribers.

Is Illumina Inc a good stock to buy?

The fair value guage provides a quick view whether ILMN is over valued or under valued. Whether Illumina Inc is cheap or expensive depends on the assumptions which impact Illumina Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ILMN.

What is Illumina Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, ILMN's PE ratio (Price to Earnings) is -14.87 and Price to Sales (PS) ratio is 4.27. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ILMN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Illumina Inc's stock?

In the past 10 years, Illumina Inc has provided -0.032 (multiply by 100 for percentage) rate of return.